WNT-SIGNAL WAY IN MYOMAUTERY
Main Article Content
Abstract
The authors made an attempt to demonstrate the role of DNA-methylation in pathogenesis of myoma utery. The epigenetic aspects based on the personal investigations of DNA-methylation of the gene WNT-ingibitory factor1 have been reviewed. The researches underlined a perspective of investigation of epigenetic mechanisms and perspective of future application of epigenetic therapy.
Study objective. To evaluate the pathogenetic relevance of DNA-methylation of WNT-ingibitory factor1 in development and pathogenesis of myomautery.
Methods. The study included 30 female patients aged 35-45 year with myoma utery who were candidates for conservative myomectomy or hysterectomy. The samples from the myoma nodules and satellite myometrium from the same patients have passed DNA extraction, «touchdown» PCR-amplification, sequencing and statistic analyses of results.
Study results. Hypermethylation in promotor region of gen of WIF1 have been found.
Conclusion. Investigation of hypermethylation of WIF1 that activate WNT-signal way, can play the key role in myoma initiation and requires further examination.Keywords
Article Details
Information about financing and conflict of interests
The authors declare that they have no apparent or potential conflicts of interest related to the publication of this article.
This work is licensed under a Creative Commons Attribution 4.0 License.
How to Cite
References
Cardozo ER, Clark AD, Banks NK, Henne MB, Stegmann BJ, Segars JH. The estimated annual cost of uterine leiomyomata in the United States. Am. J. Obstet. Gynecol. 2012; 206(3): 211. e1-e9
Wu JM, Wechter ME, Geller EJ, Nguyen TV, Visco AG. Hysterectomy rates in the Unites States. Obstet. Gynecol. 2007; 110: 1091-1095
Tikhomirov AL. Rational use of modern possibilities in the treatment of uterine myoma. M., 2007. 46 p. Russian (Тихомиров А.Л. Рациональное использование современных возможностей в лечении миомы матки. М., 2007. 46 с.)
Hu Y, Li S. Survival regulation of leukemia stem cells. Cell Mol. Life Sci. 2016; 73(5): 1039-1502
Smirnova TA, Pavshuk LI. Modern approaches to the treatment of uterine myoma in young women in order to preserve the reproductive function. Medicinskij zhurnal. 2007; 20(2): 105-107. Russian. (Смирнова Т.А., Павшук Л.И. Современные подходы к лечению миомы матки у молодых женщин с целью сохранения репродуктивной функции. Медицинский журнал. 2007. Т. 20, № 2. С. 105-107)
Bulun SE. Uterine broids. N. Engl. J. Med. 2013; 369: 1344-1355
Mgeliashvili MV, Buyanova SN, Petrakova SA, Puchkova NV. Indications for myomectomy when planning pregnancy and its influence on the women’s reproductive health. Rossiyskiy vestnik akushera-ginekologa. 2010; 5: 60-64. Russian. ( Мгелиашвили М.В., Буянова С.Н., Петракова С.А., Пучкова Н.В. Показания к миомэктомии при планировании беременности и ее влияние на репродуктивное здоровье женщин //Российский вестник акушера-гинеколога. 2010. № 5. С. 60-64)
Radzinsky VE, Totchiev GF. Мyoma: course on organsaving treatment. Informational bulletin. Status Praesens. 2014. 24 p.
Shen Q, Hua Y, Jiang W, Zhang W, Chen M, Zhu X. Effects of mifepristone on uterine leiomyoma in premenopausal women: a meta-analysis. Fertil. Steril. 2013; 100(6): 1722-1726
Duhan N. Current and emerging treatments for uterine myoma – an update. Int. J. Women’s Health. 2011; 3: 231-241
Iashvili TI, Kherodinashvili SS, Dzhorbenadze TG, Shermadini TI. Clinico-morpho-ultrasonographical characteristics of large uterine leiomyoma in females during late reproductiveand premenopausal period. Georgian. Med. News. 2006; 139: 40-43
Kondratovitch LM. The modern view on etiology, pathogenesis and modes of treatment of hysteromyoma. Rossiiskii Meditsinskii Zhurnal. 2014; 5: 36-40. Russian. (Кондратович Л.М. Современный взгляд на этиологию, патогенез и способы лечения миомы матки //Рос. мед. журнал. 2014. № 5. С. 36-40)
Sidorova IS. Uterine myoma (modern aspects of the etiology, pathogenesis, classification, and prevention). Uterine Myoma /Ed. Sidorova IS. M.: MIA, 2003: 5-66
Soliman NF, Hillard TC. Hormone replacement therapy in women with past history of endometriosis. Climacteric. 2006; 9: 325-335
Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006; 127(3): 469-480
Levanon D, Goldstein RE, Bernstein Y, Tang H, Goldenberg D, Stifani S, Paroush Z, Groner Y. Transcriptional re- pression by AML1 and LEF-1 is mediated by the TLE/Groucho co-repressors. PNAS. 1998; 95: 11590-11595
Kazanets A et al. Epigenetic silencing of tumor suppressor genes: Paradigms, puzzles, and potential. Biochim. Biophys. Acta – Rev. Cancer. The Authors. 2016; 1865(2): 275-288
Connolly R, Stearns V. Epigenetics as a therapeutic target in breast cancer. J. Mammary Gland Biol. Neoplasia. 2012; 17(3-4): 191-204
Chien AJ, Conrad WH, Moon RT. A Wnt Survival Guide: From Flies to Human Disease. J. of Investig. Dermatol. 2009; 129(7): 1614-1627
Elston MS, Clifton-Bligh RJ. Identification of Wnt family inhibitors: A pituitary tumor directed whole genome approach. Mol. and Cell. Endocrinol. 2010; 326(1-2): 48-54
Holliday R. Mechanisms for the control of gene activity during development. Biol. Rev. Camb. Philos. Soc. 1990; 65(4): 431-471
Xie J et al. Norcantharidin inhibits Wnt signal pathway via promoter demethylation of WIF-1 in human non-small cell lung cancer. Med. Oncol. 2015; 32(5): 145
Weeraratna AT. A Wnt-er wonderland – the complexity of Wnt signaling in melanoma. Cancer Metastasis Rev. 2005; 24(2): 237-250
Choy M-K et al. Genome-wide conserved consensus transcription factor binding motifs are hyper-methylated. BMC Genomics. 2010; 11: 519
Gross KL, Morton CC. Genetics and the development of fibroids. Clin. Obstet. and Gynecol. 2001; 44: 335-349
He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa L, Morin PJ, Vogelstein B, Kinzler KW. Identification of c-MYC as a target of the APC pathway. Science. 1998; 281: 1509-1512
Moumen M, Chiche A, Decraene C et al. Myc is required for β-catenin-mediated mammary stem cell amplification and tumorigenesis. Mol. Cancer. 2013; 12(1): 132
Tamai K et al. LDL-receptor-related proteins in Wnt signal transduction. Nature. 2000; 407(6803): 530-535
Tetsu O, McCormick F. b-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 1999; 398: 422-426
Bienz M. â-Catenin: a pivot between cell adhesion and Wntsignalling. Curr. Biol. 2004; 15: 64-66
Islam S, Protic O, Stortoni P et al. Complex networks of multiple factors in the pathogenesis of uterine leiomyoma. Fertil. Steril. 2013; 100(1): 178-193
Kansara M, Tsang M, Kodjabachian L, Sims NA, Trivett MK, Ehrich M, Dobrovic A, Slavin J, Choong PFM, Simmons PJ, Dawid IB, Thomas D. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J. of Clin. Invest. 2009; 119(4): 837-851
Roose J, Molenaar M, Peterson J, Hurenkamp J, Brant- jes H, Moerer P, van de Wetering M, Destree O, Clevers H. The Xenopus Wnt effector XTcf-3 interacts with Groucho-re-ated transcriptional repressors. Nature. 1998; 395: 608-612
Polakis P. Wnt signaling and cancer. Genes. Develop. 2000; 14: 1837-1851
Wright J, Herzog T, Tsui J et al. Nationwide trends in the performance of inpatient hysterectomy in the United States. Obstet. Gynecol. 2013; 122: 233-241
Chuykin IA, Lianguzova MS, Pospelov VA. Signaling pathways regulating proliferation of murine embryonic stem cells. Tsitologiya. 2007; 49(5): 370-384. Russian. (Чуйкин И.А., Лянгузова М.С., Поспелов В.А. Сигнальные пути, определяющие пролиферативную активность эмбриональных стволовых клеток мыши //Цитология. 2007. Т. 49, № 5. С. 370-384)
Hsieh JC, Rattner A, Smallwood PM, Nathans J. Biochemical characterization of Wnt-frizzled interactions using a soluble, biologically active vertebrate Wnt protein. Proc. Natl. Acad. Sci. USA. 1999; 96(7): 3546-3551
Hu Y-A, Gu X, Liu J, Yang Y, Yan Y, Zhao C. Expression pattern of Wnt inhibitor factor 1(Wif1) during the development in mouse CNS. Gene Expression Patterns. 2008; 8(7-8): 515-552
Hunter DD, Zhang M, Ferguson JW, Koch M, Brunken W. The extracellular matrix component WIF-1 is expressed during, and can modulate, retinal development. Mol. and Cell. Neurosci. 2004; 27(4): 477-488
Surmann-Schmitt C, Widmann N, Dietz U, Saeger B, Eitzinger N, Nakamura Y, Rattel M, Latham R, Hartmann C, von der Mark H, Schett G, von der Mark K, Stock M. Wif-1 is expressed at cartilage-mesenchyme interfaces and impedes Wnt3a-mediated inhibition of chondrogenesis. J. of Cell Science. 2009; 122(20): 3627-3637
Hecht A, Vleminckx K, Stemmler MP, Van Roy F, Kemler R. The p3000/CBP acetyltransferases function as transc- riptional coactivators of b-catenin in vertebrates. EMBO J. 2000; 19: 1839-1850
Ehrlich M et al. Amount and distribution of 5-methylcytosine in human DNA from different types of tissues of cells. Nucleic Acids Res. 1982; 10(8): 2709-2721
Bajekat N, Li T. Fibroids, infertility and pregnancy wastage. Hum. Reprod. Update. 2000.; 6(6): 614-620
Khalil H et al. Aging is associated with hypermethylation of autophagy genes in macrophages. Epigenetics. 2016; 11(5): 381-388
Mangioni S, Vigan P, Lattuada D, Abbiati A, Vignali M, Di Blasio AM. Over expression of the Wnt5b gene in leiomyoma cells: implications for a role of the Wnt signaling pathway in the uterine benign tumor. J. Clin. Endocrinol. Metab. 2005; 90: 5349-5355
Borsari R, Bozzini N, Junqueira CR, Soares JM Jr, Hilário SG, Baracat EC. Genic expression of the uterine leiomyoma in reproductive-aged women after treatment with goserelin. Fertil Steril. 2010 Aug; 94(3): 1072-1077. doi: 10.1016/j.fertnstert.2009.03.112
Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat. Rev. Cancer. 2013; 13(1): 11-26
Yingzi Yang. Wnt signaling in development and disease. Cell & Bioscience. 2012; 2: 14
Alvarez C et al. Silencing of tumor suppressor genes RASSF1A, SLIT2, and WIF1 by promoter hypermethylation in hereditary breast cancer. Mol. Carcinog. 2013; 52(6): 475-487